Investment thesis
Interpreting low-dose Cohort 1 data as functionally active strengthens Phase 1b results and bodes well for Phase 2 data.
The premise of this investment thesis is that a low-dose placebo effect for a gene-therapy asset held by Voyager Therapeutics (VYGR), a biotech company focused on brain disorders, is instead a true low-dose active effect. This further strengthens the possibility of positive Phase 2 results release, which would cause market appreciation of the stock in 2020.
Investing in early-stage biotechnology companies is both complicated, due to the complex nature of the assets in development